Evidence on whether reductions in excess adiposity improve patient outcomes and prevent the incidence of developing secondary disease or multiple long-term conditions.

Background

The analysis team is responsible for two datasets on life sciences activity in the UK and how it compares with other countries. One of its publications, the Bioscience and health technology sector statistics, is an official statistic and captures a detailed breakdown of where life sciences activity occurs in the UK, as well as key economic indicators such as employment and turnover. The analysis team is also responsible for publishing the Life sciences competitiveness indicators, a publication which tracks UK performance against international comparators. These two publications form the bulk of the evidence base that supports OLS policy making and key facts and figures for stakeholders. One of the ambitions of the team is to expand the range of data collected on activity in the sector to encompass a broader range of economic indicators, including Gross Value Added, R&D spending, Wages, and workforce statistics, among others.

In addition to this critical evidence base, OLS is also interested in key research questions and evidence to support the development of policy for the Life Sciences Missions, a set of disease and intervention areas identified in the Life Sciences Vision as key areas of intervention to help the NHS to solve some of the biggest healthcare problems of our generation. These range from establishing a strong evidence base on incidence and its regional distribution to identifying potential innovative technologies that could address them. Additionally, the analysis team is also very interested in deepening our understanding of the economic impact and possibilities of the broad area of genomics, as well as understanding the economic impacts and societal benefits that accrue from conducting clinical trials and other forms of R&D in the life sciences.

On the regulatory front, OLS would like to expand its understanding of the main regulatory barriers to the approval and roll-out of new, innovative technologies, as well as understanding the costs and benefits associated with these regulations. We have a limited evidence base for some products but would like to expand that understanding to be better able to assess the impact of specific regulatory interventions. We would also like to have more comprehensive data on the introduction and adoption of these technologies across the country and through the NHS.

On the investment front, we are particularly interested in building a more comprehensive evidence base on the determinants of investment in both manufacturing and R&D facilities, and how elements of both the commercial and business environment affects company location and investment decisions.

Finally, we are very interested in developing a more comprehensive understanding of the manufacturing landscape in the UK, from being able to interrogate the pipeline of new products and innovations in development, to establishing the UK’s manufacturing capabilities for health and supply chain resilience, as well as understanding key challenges faced by companies in terms of access to skilled workers and finance across the country.

Next steps

If you are keen to register your interest in working and connecting with DSIT Digital Technology and Telecoms Group and/or submitting evidence, then please complete the DSIT-ARI Evidence survey - https://dsit.qualtrics.com/jfe/form/SV_cDfmK2OukVAnirs.
Please view full details: https://www.gov.uk/government/publications/department-for-science-innovation-and-technology-areas-of-research-interest/dsit-areas-of-research-interest-2024

Related UKRI funded projects


  • MRC Centre for Translational Research in Obesity and related Metabolic Diseases

    Obesity is a major cause of premature death and disability. Obesity is particularly closely linked to the development of diabetes, with its attendant risks of blindness, kidney failure and amputation. These diseases are ...

    Funded by: MRC

    Lead research organisation: University of Cambridge

    Why might this be relevant?

    Partially relevant as it focuses on obesity and diabetes, but does not cover the broader range of diseases and conditions mentioned in the question.

  • BMI trajectories in middle to old age: methodological developments, missing data and cost-effectiveness

    The UK's aging population and increasing obesity prevalence are two of the most significant public health challenges. Currently, more than 3 million people aged 80 years and over live in the UK, and this figure is projec...

    Funded by: MRC

    Lead research organisation: University of Sheffield

    Why might this be relevant?

    Fully relevant as it specifically addresses BMI trajectories in middle to old age, obesity prevalence, and related health consequences.

  • Preventing obesity through Biologically and bEhaviorally Tailored inTERventions for you | BETTER4U

    BETTER4U aims at the identification and personalized management of all weight gain determinants to battle the increasingly rising numbers of overweight/obesity, via homogenous, globally adaptable and practically assessed...

    Funded by: Horizon Europe Guarantee

    Lead research organisation: QUEEN MARY UNIVERSITY OF LONDON

    Why might this be relevant?

    Partially relevant as it focuses on personalized weight management interventions, but does not directly address the question on the impact of reducing excess adiposity on patient outcomes and disease prevention.

  • Using genetics to test the disease consequences of higher adiposity uncoupled from its adverse metabolic effects

    Obesity is associated with many diseases in addition to type 2 diabetes and heart disease. People who are carrying too much weight are also at greater risk of diseases of the joints (e.g. osteoarthritis) , gut and intest...

    Funded by: MRC

    Lead research organisation: UNIVERSITY OF EXETER

    Why might this be relevant?

    Partially relevant as it focuses on the causal effects of excess weight on common diseases, but does not cover the impact on patient outcomes and prevention of secondary diseases as requested.

  • Preventing obesity through Biologically and bEhaviorally Tailored inTERventions for you - BETTER4U

    BETTER4U aims at the identification and personalized management of all weight gain determinants to battle the increasingly rising numbers of overweight/obesity, via homogenous, globally adaptable and practically assessed...

    Funded by: Horizon Europe Guarantee

    Lead research organisation: BRADFORD TEACHING HOSP NHS FOUND TRUST

  • Worldwide phenotypes and transitions in obesity-related multimorbidity

    Gaining too much weight without getting taller damages different organs and functions of human body and causes many diseases. This means that people with obesity tend to have multiple diseases at the same time. This is c...

    Funded by: MRC

    Lead research organisation: Imperial College London

  • The Body Volume Index (BVI) - Deployment of obesity solution for the NHS and WHO

    The Body Volume Index (BVI) is the new digital measurement solution for healthcare and obesity prevention. The Body Mass Index (BMI) was invented in 1842, and being based upon total weight and height only does not accomm...

    Funded by: Innovate UK

    Lead research organisation: SELECT SCANNING LIMITED

  • An Economic Evaluation of Obesity Prevention for UK Adults

    Obesity is a major contributor to the development of some of the most serious chronic diseases affecting the UK population, such as diabetes, coronary heart disease and cancer. Overweight and obese people suffer higher d...

    Funded by: MRC

    Lead research organisation: University of Aberdeen

  • Fighting Childhood Obesity to Stay Healthy all Over the Life (OBELISK)

    Obesity rates in late teens have increased in Europe from 6% in 1980 to 32%, with long-lasting effects on the prevalence of severe obesity, diabetes and cardiovascular disease, premature death and disability. Efficiently...

    Funded by: Horizon Europe Guarantee

    Lead research organisation: BETA TECHNOLOGY LIMITED

  • Beta-defensins in the prevention of obesity

    Obesity has reached epidemic levels in the UK and globally: both in adults and (most worrying in the longer term) in children. Obesity and obesity-related disease (including type 2 diabetes, heart disease, asthma and som...

    Funded by: MRC

    Lead research organisation: University of Edinburgh